These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 20413687

  • 1. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
    Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ.
    Am J Pathol; 2010 Jun; 176(6):2840-7. PubMed ID: 20413687
    [Abstract] [Full Text] [Related]

  • 2. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ.
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [Abstract] [Full Text] [Related]

  • 3. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 4. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
    Sugahara K, Maeda Y, Shimano K, Murase M, Mochiduki S, Takemoto K, Kakimoto T, Utsumi H, Oshita K, Kataoka H.
    J Immunol Res; 2019 Sep 15; 2019():5821589. PubMed ID: 31930150
    [Abstract] [Full Text] [Related]

  • 5. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.
    Wolf VL, Taylor EB, Ryan MJ.
    Physiol Rep; 2019 May 15; 7(10):e14059. PubMed ID: 31124322
    [Abstract] [Full Text] [Related]

  • 6. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 15; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 7. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr 15; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

  • 8. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.
    Arthritis Rheum; 2006 Oct 15; 54(10):3277-83. PubMed ID: 17009262
    [Abstract] [Full Text] [Related]

  • 9. Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
    Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
    Clin Immunol; 2016 Aug 15; 169():139-147. PubMed ID: 27392463
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
    Dang WZ, Li H, Jiang B, Nandakumar KS, Liu KF, Liu LX, Yu XC, Tan HJ, Zhou C.
    Phytomedicine; 2019 Sep 15; 62():152965. PubMed ID: 31129432
    [Abstract] [Full Text] [Related]

  • 11. Sex-specific differences in SLE - Significance in the experimental setting of inflammation and kidney damage in MRL-Faslpr mice.
    Saurin S, Meineck M, Claßen P, Boedecker-Lips SC, Pautz A, Weinmann-Menke J.
    Autoimmunity; 2024 Dec 15; 57(1):2377098. PubMed ID: 39004847
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of receptor interacting protein kinase-1 (RIPK1) in the treatment of murine lupus.
    Peng L, Wang P, Xu X, Chen D, Xu F, Yang F, Yang S, Xia H, Liu ZH, Qin W.
    Lupus Sci Med; 2024 Jun 21; 11(1):. PubMed ID: 38906550
    [Abstract] [Full Text] [Related]

  • 13. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
    Gu Z, Tan W, Ji J, Feng G, Meng Y, Da Z, Guo G, Xia Y, Zhu X, Shi G, Cheng C.
    Aging (Albany NY); 2016 May 21; 8(5):1102-14. PubMed ID: 27048648
    [Abstract] [Full Text] [Related]

  • 14. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 21; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 15. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
    Lenda DM, Stanley ER, Kelley VR.
    J Immunol; 2004 Oct 01; 173(7):4744-54. PubMed ID: 15383612
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice.
    Jonsson CA, Erlandsson M, Svensson L, Mölne J, Carlsten H.
    Cell Immunol; 1999 Nov 01; 197(2):136-44. PubMed ID: 10607431
    [Abstract] [Full Text] [Related]

  • 17. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.
    J Immunol; 2011 Oct 01; 187(7):3840-53. PubMed ID: 21880982
    [Abstract] [Full Text] [Related]

  • 18. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
    Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, Perro M, Klein C, Nickerson KM, Shlomchik MJ.
    Arthritis Rheumatol; 2021 May 01; 73(5):826-836. PubMed ID: 33277983
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
    Jonsson CA, Svensson L, Carlsten H.
    Clin Exp Immunol; 1999 Jun 01; 116(3):534-41. PubMed ID: 10361247
    [Abstract] [Full Text] [Related]

  • 20. Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice.
    Soto M, Delatorre N, Hurst C, Rodgers KE.
    Front Immunol; 2020 Jun 01; 11():1572. PubMed ID: 32793221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.